If you are lucky enough to have $3,000 to invest into the share market, then now could be a great time to deploy this cash.
That's because many ASX shares are now trading at a deep discount to what investors were willing to pay just a matter of a few weeks ago.
But which top ASX shares could be good options for this $3,000? Let's look at three that analysts rate as buys:
Pro Medicus Limited (ASX: PME)
The first top ASX share that could be a top option for a $3,000 investment is Pro Medicus.
It is a leading global healthcare technology company that provides medical imaging software and services to hospitals, imaging centres, and healthcare groups globally. This includes offerings such as RIS, PACS, AI and e-health solutions.
The key product in its portfolio is the Visage 7 solution, which is a leading platform for medical imaging, known for its speed, scalability, and cloud capabilities.
Bell Potter is likely to see the market selloff as a buying opportunity for investors. Especially given Pro Medicus' very positive outlook. It recently said:
The PME full stack solution continues to wipe the floor with competitors – 10 contract announcements in the LTM including two new academic medical centres clients. FY25/26 revenues upgraded by 4% and 2% respectively. In addition we expect further growth in the cardiology space with the first small scale implementation to take place in April 2025.
Bell Potter has a buy rating and $330.00 price target on its shares. This implies potential upside of almost 45% for investors over the next 12 months.
Lovisa Holdings Ltd (ASX: LOV)
Another top ASX share that analysts think could be a good option for a $3,000 investment is Lovisa.
It is a fast-fashion jewellery retailer with a rapidly growing store network. Every week, it delivers 150 new styles to stores, keeping shoppers coming back week after week.
Bell Potter is also a big fan of Lovisa and is tipping it as a buy right now. Especially with its shares trading on lower than normal multiples. It said:
We continue see catalysts in both new stores and LFL sales ahead considering the notable recovery into 2H25, higher 2H skew in Americas and healthy new openings in broader Europe (ex-UK/France/Germany). The stock continues to trade at a P/E of sub-30x on a 12-month forward basis (BPe) and we see valuation support.
Bell Potter has a buy rating and $30.00 price target on Lovisa's shares. This suggests that upside of 24% is possible for investors from current levels.
